---
title: "Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290252332.md"
description: "Sonoma Pharmaceuticals expanded its at-the-market equity offering capacity to $3,641,703 via a prospectus supplement filed on June 18, 2026. Previously, the company sold 173,073 shares for $574,633 under an agreement with Ladenburg Thalmann & Co. This move aims to provide operational funding but may dilute shareholders. TipRanks' AI analyst rates SNOA as Neutral due to weak financials and bearish trends, despite modest leverage and a positive commercial agreement."
datetime: "2026-06-18T22:41:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290252332.md)
  - [en](https://longbridge.com/en/news/290252332.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290252332.md)
generator: "portal-rs"
---

# Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity

Sonoma Pharmaceuticals ( (SNOA) ) has shared an announcement.

On September 26, 2025, Sonoma Pharmaceuticals, Inc. entered into an at-the-market issuance sales agreement with Ladenburg Thalmann & Co. to sell shares of its common stock under an existing shelf registration, and between that date and the current reporting date it sold 173,073 shares for total proceeds of $574,633. On June 18, 2026, Sonoma filed a supplement to its prospectus with the U.S. Securities and Exchange Commission to raise the aggregate offering capacity under the program to $3,641,703, a move that expands the company’s flexibility to access equity capital and may dilute existing shareholders while providing additional funding for its operations.

**Spark’s Take on SNOA Stock**

According to Spark, TipRanks’ AI Analyst, SNOA is a Neutral.

The score is held down primarily by weak financial quality—continued losses and significant negative free cash flow—along with bearish technical trends. Offsetting these risks are modest leverage and a positive commercial event (the Kenvue supply agreement), but valuation support is limited given negative earnings and no dividend data.

To see Spark’s full report on SNOA stock,  
 click here. 

**More about Sonoma Pharmaceuticals**

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceuticals company focused on developing and marketing prescription and over-the-counter products, with its primary business centered on dermatology and related therapeutic areas. The company operates in the U.S. healthcare and life sciences industry, leveraging capital markets access to support ongoing product development and commercialization efforts.

**Average Trading Volume:** 219,913

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $3.82M

### Related Stocks

- [SNOA.US](https://longbridge.com/en/quote/SNOA.US.md)
- [KVUE.US](https://longbridge.com/en/quote/KVUE.US.md)

## Related News & Research

- [Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting](https://longbridge.com/en/news/296409897.md)
- [Sonoma Pharmaceuticals special shareholder meeting lacked quorum, chairman canceled session](https://longbridge.com/en/news/296403757.md)
- [BioCryst Pharmaceuticals (BCRX), What Is Behind The Fresh Attention Now?](https://longbridge.com/en/news/296688974.md)
- [Great Lakes Advisors LLC Acquires Shares of 29,800 Supernus Pharmaceuticals, Inc. $SUPN](https://longbridge.com/en/news/296676820.md)
- [$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296632631.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**